Meridian Bioscience's Q2 Revenues Increase 30% To $111M, Highest In Company History
Meridian Bioscience Inc (NASDAQ:VIVO) reported a 30% increase in Q2 sales to $111.2 million, the highest in the company's history, with both segments ahead of expectations, beating the consensus of $99.54 million. Revenues from the life science division grew 32% Y/Y to $70.1 million. Diagnostic segment sales rose 29% to $41.1 million.…
Benzinga ·
Benzinga
